Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MND-SMART
2019-000099-41Phase 2Unknown
- Sponsor
- University of Edinburgh
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of memantine and trazodone in motor neuron disease (MND), amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS) and 1 more (3 arms), sponsored by University of Edinburgh. Primary endpoints: ALS Functional Rating Scale-Revised and Overall survival. Status: unknown.
02
Drugs
memantinetrazodone
03
Conditions
motor neuron disease (MND)amyotrophic lateral sclerosis (ALS)primary lateral sclerosis (PLS)progressive muscular atrophy (PMA)
Beyond the preview
Go deeper on 2019-000099-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000099-41.